Comparison of the developmental effects of 5-methoxy-N,N-diisopropyltryptamine (Foxy) to (+/-)-3,4-methylenedioxymethamphetamine (ecstasy) in rats.
BACKGROUND
We have previously shown that (+/-)-3,4-methylenedioxymethamphetamine (MDMA) treatment from postnatal days (P)11 to P20 leads to learning and memory deficits when the animals are tested as adults. Recently, the club drug 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT) has gained popularity.


OBJECTIVE
Due to the similarities between MDMA and 5-MeO-DIPT and the substitution of 5-MeO-DIPT for MDMA, the purpose of this study was to compare the developmental effects of these drugs.


METHODS
Within a litter, animals were treated from P11 to P20 with either MDMA, 5-MeO-DIPT, or saline.


RESULTS
MDMA-treated animals showed increased anxiety in a measure of defensive marble burying, as well as deficits in spatial and path integration learning. 5-MeO-DIPT-treated animals showed spatial learning deficits; however, there were no deficits observed in spatial memory or path integration learning. 5-MeO-DIPT-treated animals also showed hyperactivity in response to a challenge dose of methamphetamine.


CONCLUSIONS
The results show that treatment with either 5-MeO-DIPT or MDMA during development results in cognitive deficits and other behavioral changes but the pattern of effects is distinct for each drug.
Skelton
Matthew R
MR
Division of Neurology, Cincinnati Children's Research Foundation and University of Cincinnati College of Medicine, Cincinnati, OH 45229, USA.
Schaefer
Tori L
TL
Herring
Nicole R
NR
Grace
Curtis E
CE
Vorhees
Charles V
CV
Williams
Michael T
MT
D000375:Aging / Q000523:psychology*; D000818:Animals; D001007:Anxiety / Q000523:psychology; D001835:Body Weight / Q000187:drug effects; D003463:Cues; D005260:Female; D006213:Hallucinogens / Q000494:pharmacology*; D007858:Learning / Q000187:drug effects; D008029:Lighting; D018782:Maze Learning / Q000187:drug effects; D008568:Memory / Q000187:drug effects; D009043:Motor Activity / Q000187:drug effects; D018817:N-Methyl-3,4-methylenedioxyamphetamine / Q000494:pharmacology*; D010111:Oxymorphone / Q000031:analogs & derivatives* / Q000494:pharmacology; D011247:Pregnancy; D051381:Rats; D017207:Rats, Sprague-Dawley
D006213:Hallucinogens; C042285:6-fluoro-6-desoxyoxymorphone; D010111:Oxymorphone; D018817:N-Methyl-3,4-methylenedioxyamphetamine